Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Income from Continuing Operations of 55639000.0 for Q1 2026, down 12.36% year-over-year from 63486692.67 in Q1 2025, and down 17.12% quarter-over-quarter from 47505000.0 in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 11 years of Income from Continuing Operations data on file, last reported at 55639000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 55639000.0, down 12.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 202643000.0 (down 20.05% YoY), and the FY2025 annual result was 196539000.0, up 24.58% from the prior year.
- Income from Continuing Operations slipped to 55639000.0 in Q1 2026 per RYTM's latest filing, from 47505000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 32261000.0 in Q2 2024 and troughed at 141372000.0 in Q1 2024.
- A 5-year average of 51661058.82 and a median of 46595000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations tumbled 220.07% in 2022, then jumped 64.97% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 42493000.0 in 2022, then increased by 2.02% to 41633000.0 in 2023, then slipped by 4.07% to 43328000.0 in 2024, then dropped by 9.64% to 47505000.0 in 2025, then declined by 17.12% to 55639000.0 in 2026.
- Business Quant data shows RYTM's Income from Continuing Operations at 55639000.0 in Q1 2026, 47505000.0 in Q4 2025, and 52904000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | -55.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.64 Mn |
| Dec 31, 2025 | -47.51 Mn |
| Sep 30, 2025 | -52.90 Mn |
| Jun 30, 2025 | -46.60 Mn |
| Mar 31, 2025 | -49.52 Mn |
| Dec 31, 2024 | -43.33 Mn |
| Sep 30, 2024 | -43.69 Mn |
| Jun 30, 2024 | -32.26 Mn |
| Mar 31, 2024 | -141.37 Mn |
| Dec 31, 2023 | -41.63 Mn |
| Sep 30, 2023 | -44.16 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -44.87 Mn |
| Mar 31, 2022 | -52.53 Mn |
| Dec 31, 2021 | -50.86 Mn |
| Sep 30, 2021 | -35.11 Mn |
| Jun 30, 2021 | -35.39 Mn |